ALLK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Allakos's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Allakos's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Allakos's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allakos's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Allakos's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Allakos is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Allakos (NAS:ALLK) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Allakos's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Harlan Baird Radford | officer: Chief Financial Officer | C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125 |
Graham Neil Murray Hamilton | director | 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520 |
Everett Rand Sutherland | director | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Paul Edward Walker | director | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Daniel Janney | director | PO BOX 7414, JACKSON WY 83002 |
Amy L Ladd | director | INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086 |
Craig A. Paterson | officer: Chief Medical Officer | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Margaret Nell Fitzgerald | officer: General Counsel and Secretary | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Steven P James | director | C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Adam Tomasi | officer: COO, CFO and Secretary | ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Robert Alexander | director, officer: President and CEO | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Rasmussen Henrik S Md | officer: Chief Medical Officer | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
John P Mckearn | director, 10 percent owner | 5820 NANCY DRIVE, SAN DIEGO CA 92121 |
Peter A Hudson | 10 percent owner | 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067 |
From GuruFocus
By GuruFocus News • 04-02-2025
By GuruFocus Research • 05-10-2024
By PRNewswire • 12-19-2024
By Marketwired • 08-07-2024
By ACCESSWIRE • 02-12-2024
By Business Wire • 04-02-2025
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 04-02-2025
By GuruFocus News • 02-04-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.